Skip to main content
. Author manuscript; available in PMC: 2011 Mar 18.
Published in final edited form as: Adv Drug Deliv Rev. 2009 Nov 24;62(4-5):518–531. doi: 10.1016/j.addr.2009.11.021

Table 6.

Summary of surface modifications of bioconjugate-based nanocarriers investigated for targeting anti-HIV drugs to different cells/tissues/organs

Anti-HIV drugs Surface modifications Cells/tissues/organs Reference(s)
SQV, Tat peptide Conjugation of (a) SQV to PEG, (b)SQV to PEG-biotin, (c) SQV-Tat to PEG, (d) SQV-Tat-stearate to PEG, (e)biotin to Tat, (f)Tat to PEG and (g)Tat-biotin to PEG HIV-1 infected MT-2 cells [97, 98]
No drug Conjugation of (a)various copies of fMLF to PEG (different shapes and sizes) and (b)four copy fMLF with four copy digoxigenin to PEG Differentiated HL-60 cells (expressing formyl peptide receptors) and mouse peritoneal macrophage cells [99]
No drug Conjugation of (a)various copies of fMLF to PEG (different shapes and sizes) and (b)various copies of fMLF to peptide-based PEG (different sizes) (a)Differentiated U937 macrophage-like cells (expressing formyl peptide receptors) and (b)tissue distribution following IP administration in mice [100, 101]